Öğr. Gör. İZGİ BAYRAKTAR ALKAN

Yayın Ağı

Makaleler 16

1. Beyond dose: Antipsychotic risk categories and sex-specific vulnerability to hyperprolactinemia in real-world longitudinal care

Öztürk Yalçın Z., BAYRAKTAR ALKAN İ., Kaşıkcı M., YALÇIN N., ÖZÇELİK EROĞLU E., ANIL YAĞCIOĞLU A. E., et al.

Psychoneuroendocrinology , cilt.188, 2026 (SCI-Expanded, Scopus)

2. A prospective feasibility study evaluating the implementation of model-informed precision dosing in critically ill children

BAYRAKTAR ALKAN İ., Kaşıkcı M., BENEK Z., Allegaert K., Egehan Oruncu B., KESİCİ S., et al.

Frontiers in Pharmacology , cilt.17, 2026 (SCI-Expanded, Scopus)

3. Alterations of appetite-regulating hormones in risperidone treated children and adolescents-a post hoc analysis of the SPACe study

Liang J., de Winter B. C. M., Hermans R. A., Kloosterboer S. M., Kuckuck S., Bayraktar İ., et al.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY , cilt.91, sa.7, ss.2090-2094, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

4. Comparative efficacy and safety of alternatives to sodium valproate in the management of bipolar affective disorder in people of child-bearing age: a narrative review by the European Society of Clinical Pharmacy's mental health specialist interest group

Fitzgerald I., YALÇIN N., Eiden B., Gittins R., Magni E., Humbert-Claude M., et al.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY , cilt.47, sa.3, ss.666-675, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

5. Medication adherence and attitudes in adolescent psychiatry: Key influences

Bayraktar İ., YALÇIN N., NALBANT K., Kultur E. c., Demirkan K.

CLINICAL CHILD PSYCHOLOGY AND PSYCHIATRY , cilt.30, sa.2, ss.516-528, 2025 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

6. Pharmacogenetic Variant Related Higher-Than-Expected Clozapine Concentrations and Clozapine/Norclozapine Ratios in a Patient With Treatment-Resistant Schizoaffective Disorder A Case Report

Yalçın N., Bayraktar İ., Akyol A., Deger I., İman M. F., Mutlu E., et al.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY , cilt.45, sa.2, ss.163-165, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

7. Optimizing Individualized Antimicrobial Dosing in Pediatric Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Yalçın N., Dirik Y., Bayraktar İ., Umaroğlu M., Allegaert K.

CLINICAL DRUG INVESTIGATION , cilt.45, sa.1, ss.1-16, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

8. Advancing patient care: novel scales for assessing adherence and attitudes toward medication among adolescents with psychiatric disorders and their parents

Bayraktar İ., Yalcin N., Nalbant K., Karabulut E., Kultur E. C., Demirkan K.

EUROPEAN CHILD & ADOLESCENT PSYCHIATRY , cilt.33, sa.12, ss.4393-4403, 2024 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

9. Effect of inflammation on voriconazole levels in patients with invasive pulmonary aspergillosis

BAKIR EKİNCİ P., BAYRAKTAR ALKAN İ., ER A. G., Pinar A., İNKAYA A. Ç., DEMİRKAN S. K., et al.

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES , sa.10, 2024 (SCI-Expanded, Scopus)

10. Concomitant drug use of nirmatrelvir/ritonavir and CYP3A4-modulating antimicrobial agents: an approach for drug use

Visscher R., Yalçın N., Bayraktar İ., Bayraktar-Ekincioglu A.

EUROPEAN JOURNAL OF HOSPITAL PHARMACY , cilt.31, sa.2, ss.180-182, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

11. Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health

Stuhec M., Hahn M., Taskova I., Bayraktar İ., Fitzgerald I., Molitschnig L., et al.

INTERNATIONAL JOURNAL OF CLINICAL PHARMACY , cilt.45, sa.5, ss.1286-1292, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen

Liang J., Ringeling L. T., Hermans R. A., Bayraktar İ., Bosch T. M., Egberts K. M., et al.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY , cilt.19, sa.8, ss.501-509, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

13. Is everyone invited to the discussion table? A bibliometric analysis COVID-19-related mental health literature

Yalcin N., Bayraktar İ., Karabulut E., de Filippis R., Jaguga F., Karaliuniene R., et al.

GLOBAL MENTAL HEALTH , cilt.9, ss.366-374, 2022 (SCI-Expanded, Scopus)

14. Is samidorphan adjunction a beacon of hope for olanzapine-induced metabolic syndrome?

Bayraktar İ., Balcioglu Y. H.

DUSUNEN ADAM-JOURNAL OF PSYCHIATRY AND NEUROLOGICAL SCIENCES , cilt.35, sa.2, ss.138-140, 2022 (ESCI, Scopus, TRDizin)

15. Asymptomatic Eosinophilia Induced by Systemic Colistin Therapy: A Brief Case Report

BAYRAKTAR ALKAN İ., KARA E., SÖNMEZER M. Ç., DEMİRKAN S. K., TOPÇUOĞLU M. A.

Türkiye Klinikleri Journal of Case Reports , cilt.30, sa.1, 2022 (TRDizin)

16. The potential interaction between COVID-19 vaccines and clozapine: A novel approach for clinical trials

Bayraktar İ., Yalçın N., Demirkan K.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , cilt.75, sa.8, 2021 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 2

1. Significant Impact of Total Duration of Clozapine Use on Norclozapine Serum Levels: A Multivariate Retrospective Analysis

BAYRAKTAR İ., OCAK M., YALÇIN N., GÜREL Ş. C., DEMİRKAN S. K.

American College of Clinical Pharmacy Annual Meeting, Dallas-Texas, Amerika Birleşik Devletleri, 11 - 14 Kasım 2023, cilt.6, ss.1501, (Özet Bildiri)

2. EVALUATION OF ATTITUDES TOWARDS PSYCHOTROPIC MEDICATIONS IN ADOLESCENTS WITH A DEVELOPED NEW SCALE

BAYRAKTAR İ., YALÇIN N., KARABULUT E., NALBANT K., ÇENGEL KÜLTÜR S. E., DEMİRKAN S. K.

50th European Society of Clinical Pharmacy (ESCP) Symposium on Clinical Pharmacy, Polypharmacy and ageing, Prague, Çek Cumhuriyeti, 19 Ekim 2022, cilt.44, ss.1500, (Özet Bildiri)

Yayınlar & Eserler